Toyojiro Matsuishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Toyojiro Matsuishi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Go Kawano
Department of Pediatrics, St Mary's Hospital, Fukuoka, Japan
2 shared publicationsMunetsugu Hara
Department of Pediatrics and Child Health Kurume University School of Medicine Fukuoka Japan
2 shared publicationsTakaoki Yokochi
Department of Paediatrics, St Mary's Hospital, Kurume, Fukuoka, Japan
2 shared publicationsTomoyuki Takahashi
Division of Gene Therapy and Regenerative Medicine, Cognitive and Molecular Research Institute of Brain Diseases, Kurume University School of Medicine, Kurume, Japan
2 shared publicationsYukihiro Akita
Department of Pediatrics, St Mary's Hospital, Fukuoka, Japan
2 shared publications- Yushiro Yamashita
Department of Pediatrics and Child Health Kurume University School of Medicine Kurume Japan
2 shared publications
Latest Publications
- 4 April 2026
- Published by Elsevier in Brain and Development
- Vol. 48 (3) , 104531
Utility of the Rett syndrome behavior questionnaire (RSBQ) for Japanese patients with Rett syndrome: A pilot study
- 4 April 2026
- Published by Elsevier in Brain and Development
- Vol. 48 (3) , 104531
Utility of the Rett syndrome behavior questionnaire (RSBQ) for Japanese patients with Rett syndrome: A pilot study
- 8 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178352
Ghrelin restores D1 receptor-mediated dopamine neurotransmission and enhances attentive behaviour in Mecp2 KO mice
- 8 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178352
Ghrelin restores D1 receptor-mediated dopamine neurotransmission and enhances attentive behaviour in Mecp2 KO mice
- Open Access
- 15 May 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (5) , e05811
Perampanel markedly improved clinical seizures in a patient with a Rett‐like phenotype and 960‐kb deletion on chromosome 9q34.11 including the STXBP1
Intractable epilepsy was successfully controlled using perampanel, an α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid‐type glutamate receptor antagonist, in a 27‐year‐old woman who presented with a Rett syndrome‐like phenotype and novel 960‐kb deletion involving syntaxin‐binding protein 1 on chromosome 9q34.11. Perampanel may be an effective antiepileptic drug for intractable epilepsy associated with STXBP1 mutations.
- 15 May 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (5) , e05811
Open AccessPerampanel markedly improved clinical seizures in a patient with a Rett‐like phenotype and 960‐kb deletion on chromosome 9q34.11 including the STXBP1
Intractable epilepsy was successfully controlled using perampanel, an α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid‐type glutamate receptor antagonist, in a 27‐year‐old woman who presented with a Rett syndrome‐like phenotype and novel 960‐kb deletion involving syntaxin‐binding protein 1 on chromosome 9q34.11. Perampanel may be an effective antiepileptic drug for intractable epilepsy associated with STXBP1 mutations.
- Open Access
- 20 May 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Case Report: Rituximab Improved Epileptic Spasms and EEG Abnormalities in an Infant With West Syndrome and Anti-NMDAR Encephalitis Associated With APECED
Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is a rare autosomal recessive disorder caused by a mutation in the autoimmune regulator gene. Patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy typically exhibit hypoparathyroidism, adrenocortical failure, and chronic mucocutaneous candidiasis. There are only a few case reports of autoimmune encephalitis during autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, but not as an initial manifestation. Furthermore, there are no reports of patients with infantile spasms/West syndrome with autoimmune encephalitis, partly because the median age for paediatric patients with anti-N-methyl-D-aspartate receptor encephalitis, which is the most frequent and best characterised in paediatric autoimmune encephalitides, is 13–14 years. Herein, we present a case of a 3-month-old infant with autoimmune encephalitis as an initial manifestation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy who later developed infantile spasms/West syndrome.Case Presentation: A 3-month-old girl was admitted to our hospital with a fever, involuntary movements in all four limbs, and right-side facial palsy. Acute central nervous system demyelination diseases were suspected from neuroimaging findings and the presence of the cerebrospinal fluid oligoclonal band. She did not respond to multiple methylprednisolone pulse therapies and later developed infantile spasms/West syndrome and diabetes mellitus. Rituximab, a chimeric mouse/human monoclonal antibody directed against human CD20 which depletes B cells, was initially administered as a treatment for autoimmune encephalitis. Unexpectedly, this treatment resulted in complete spasm cessation and resolution of hypsarrhythmia. The patient eventually showed severely delayed developmental milestones, and her electroencephalography findings showed periodic generalised slow spike-and-wave pattern.Conclusions: Despite the limited ability to extrapolate findings from a single case, rituximab's effects may suggest that B cells play a crucial role in infantile spasms/West syndrome mechanisms; use of rituximab as an aetiology-specific treatment for infantile spasms/West syndrome patients with autoimmune encephalitis or its effectiveness for infantile spasms/West syndrome patients with other underlying mechanisms warrants further investigation.
- 20 May 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Open AccessCase Report: Rituximab Improved Epileptic Spasms and EEG Abnormalities in an Infant With West Syndrome and Anti-NMDAR Encephalitis Associated With APECED
Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is a rare autosomal recessive disorder caused by a mutation in the autoimmune regulator gene. Patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy typically exhibit hypoparathyroidism, adrenocortical failure, and chronic mucocutaneous candidiasis. There are only a few case reports of autoimmune encephalitis during autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, but not as an initial manifestation. Furthermore, there are no reports of patients with infantile spasms/West syndrome with autoimmune encephalitis, partly because the median age for paediatric patients with anti-N-methyl-D-aspartate receptor encephalitis, which is the most frequent and best characterised in paediatric autoimmune encephalitides, is 13–14 years. Herein, we present a case of a 3-month-old infant with autoimmune encephalitis as an initial manifestation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy who later developed infantile spasms/West syndrome.Case Presentation: A 3-month-old girl was admitted to our hospital with a fever, involuntary movements in all four limbs, and right-side facial palsy. Acute central nervous system demyelination diseases were suspected from neuroimaging findings and the presence of the cerebrospinal fluid oligoclonal band. She did not respond to multiple methylprednisolone pulse therapies and later developed infantile spasms/West syndrome and diabetes mellitus. Rituximab, a chimeric mouse/human monoclonal antibody directed against human CD20 which depletes B cells, was initially administered as a treatment for autoimmune encephalitis. Unexpectedly, this treatment resulted in complete spasm cessation and resolution of hypsarrhythmia. The patient eventually showed severely delayed developmental milestones, and her electroencephalography findings showed periodic generalised slow spike-and-wave pattern.Conclusions: Despite the limited ability to extrapolate findings from a single case, rituximab's effects may suggest that B cells play a crucial role in infantile spasms/West syndrome mechanisms; use of rituximab as an aetiology-specific treatment for infantile spasms/West syndrome patients with autoimmune encephalitis or its effectiveness for infantile spasms/West syndrome patients with other underlying mechanisms warrants further investigation.
- 23 April 2016
- Published by Elsevier in Brain and Development
- Vol. 38 (9) , 875-879
Acute encephalopathy with biphasic seizures and late reduced diffusion associated with staphylococcal toxic shock syndrome caused by burns
- 23 April 2016
- Published by Elsevier in Brain and Development
- Vol. 38 (9) , 875-879
Acute encephalopathy with biphasic seizures and late reduced diffusion associated with staphylococcal toxic shock syndrome caused by burns
- Open Access
- 9 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10)
Correction: Age-Specific Sex-Related Differences in Infections: A Statistical Analysis of National Surveillance Data in Japan
- 9 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10)
Open AccessCorrection: Age-Specific Sex-Related Differences in Infections: A Statistical Analysis of National Surveillance Data in Japan
- 18 July 2011
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 29 (8) , 899-902
Ghrelin levels are reduced in Rett syndrome patients with eating difficulties
Most patients with Rett syndrome (RTT) have both gastrointestinal problems and somatic growth failure, including microcephaly. Ghrelin is a peptide hormone involved in growth hormone secretion, interdigestive motility, and feeding behavior. Plasma ghrelin assays have previously been described for other neurodevelopmental disorders. To examine the pathophysiology of RTT, we measured plasma levels of ghrelin in patients with RTT. A case–control study examining plasma levels of ghrelin, serum growth hormone, and insulin‐like growth factor‐1 (IGF‐1) was performed on 27 patients with RTT and 53 controls. Plasma levels of total (T)‐ and octanoyl (O)‐ghrelin were significantly lower in patients with RTT than in controls. Plasma levels of T‐ghrelin correlated significantly with serum IGF‐1 levels and head circumference. Significantly lower levels of plasma T‐ghrelin and O‐ghrelin were observed in RTT patients with eating difficulties, while lower levels of plasma T‐ghrelin were observed in RTT patients with constipation, in comparison to patients without either of these symptoms. Alterations in plasma ghrelin levels may reflect various clinical symptoms and signs in RTT patients, including growth failure, acquired microcephalus, autonomic nerve dysfunction, and feeding difficulties. We describe the role of ghrelin in RTT and suggest this peptide as a novel biological marker in patients with RTT.
- 18 July 2011
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 29 (8) , 899-902
Ghrelin levels are reduced in Rett syndrome patients with eating difficulties
Most patients with Rett syndrome (RTT) have both gastrointestinal problems and somatic growth failure, including microcephaly. Ghrelin is a peptide hormone involved in growth hormone secretion, interdigestive motility, and feeding behavior. Plasma ghrelin assays have previously been described for other neurodevelopmental disorders. To examine the pathophysiology of RTT, we measured plasma levels of ghrelin in patients with RTT. A case–control study examining plasma levels of ghrelin, serum growth hormone, and insulin‐like growth factor‐1 (IGF‐1) was performed on 27 patients with RTT and 53 controls. Plasma levels of total (T)‐ and octanoyl (O)‐ghrelin were significantly lower in patients with RTT than in controls. Plasma levels of T‐ghrelin correlated significantly with serum IGF‐1 levels and head circumference. Significantly lower levels of plasma T‐ghrelin and O‐ghrelin were observed in RTT patients with eating difficulties, while lower levels of plasma T‐ghrelin were observed in RTT patients with constipation, in comparison to patients without either of these symptoms. Alterations in plasma ghrelin levels may reflect various clinical symptoms and signs in RTT patients, including growth failure, acquired microcephalus, autonomic nerve dysfunction, and feeding difficulties. We describe the role of ghrelin in RTT and suggest this peptide as a novel biological marker in patients with RTT.
- 25 January 2010
- Published by Wiley in Pediatrics International
- Vol. 52 (1) , 44-50
Developmental pattern of urinary bile acid profile in preterm infants
Background: Bile acid metabolism in preterm infants is yet to be fully characterized. We compared the developmental pattern of urinary bile acid profiles in ten infants born at gestational ages from 25 to 33 weeks with previous data from full‐term infants from birth to about 7 months of age.Methods: Gas chromatography–mass spectrometry was performed on serial samples.Results: Total urinary bile acid concentrations gradually increased until 1 to 2 months of age. After this peak of excretion (30 to 60 µmol/mmol creatinine), total urinary bile acid concentrations gradually decreased to less than 20 µmol/mmol creatinine. The percentage of usual bile acids (mainly cholic acid) relative to total urinary total bile acids gradually deceased from approximately 30% at birth to less than 15% at 7 months of age. On the other hand, 1β‐hydroxylated bile acids (mainly 1β,3α,7α,12α‐tetrahydroxy‐5β‐cholan‐24‐oic acid) relative to total urinary bile acids were increased gradually from 60% at birth to reach 70% to 80% at 1 month of age. The percentage of 1β‐hydroxylated bile acids relative to total urinary bile acids then remained stable at a high percentage (70% to 90%) until the age of 7 months.Conclusion: Physiological cholestasis in preterm infants persists longer than in full‐term infants. Moreover, as large amounts of cholic and 1β,3α,7α,12α‐tetrahydroxy‐5β‐cholan‐24‐oic acids were detected in urine from preterm infants during this study, the 25‐hydroxylation pathway may be particularly important for bile acid synthesis in early preterm infants.
- 25 January 2010
- Published by Wiley in Pediatrics International
- Vol. 52 (1) , 44-50
Developmental pattern of urinary bile acid profile in preterm infants
Background: Bile acid metabolism in preterm infants is yet to be fully characterized. We compared the developmental pattern of urinary bile acid profiles in ten infants born at gestational ages from 25 to 33 weeks with previous data from full‐term infants from birth to about 7 months of age.Methods: Gas chromatography–mass spectrometry was performed on serial samples.Results: Total urinary bile acid concentrations gradually increased until 1 to 2 months of age. After this peak of excretion (30 to 60 µmol/mmol creatinine), total urinary bile acid concentrations gradually decreased to less than 20 µmol/mmol creatinine. The percentage of usual bile acids (mainly cholic acid) relative to total urinary total bile acids gradually deceased from approximately 30% at birth to less than 15% at 7 months of age. On the other hand, 1β‐hydroxylated bile acids (mainly 1β,3α,7α,12α‐tetrahydroxy‐5β‐cholan‐24‐oic acid) relative to total urinary bile acids were increased gradually from 60% at birth to reach 70% to 80% at 1 month of age. The percentage of 1β‐hydroxylated bile acids relative to total urinary bile acids then remained stable at a high percentage (70% to 90%) until the age of 7 months.Conclusion: Physiological cholestasis in preterm infants persists longer than in full‐term infants. Moreover, as large amounts of cholic and 1β,3α,7α,12α‐tetrahydroxy‐5β‐cholan‐24‐oic acids were detected in urine from preterm infants during this study, the 25‐hydroxylation pathway may be particularly important for bile acid synthesis in early preterm infants.
- Open Access
- 1 May 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (9) , 1346-1350
Elevated Levels of Anti‐CD9 Antibodies in the Cerebrospinal Fluid of Patients with Subacute Sclerosing Panencephalitis
Subacute sclerosing panencephalitis (SSPE) is a slowly progressive and highly lethal disease of the central nervous system. Although the primary caus
- 1 May 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (9) , 1346-1350
Open AccessElevated Levels of Anti‐CD9 Antibodies in the Cerebrospinal Fluid of Patients with Subacute Sclerosing Panencephalitis
Subacute sclerosing panencephalitis (SSPE) is a slowly progressive and highly lethal disease of the central nervous system. Although the primary caus
- Open Access
- 1 January 1997
- Published by West-Japanese Society of Orthopedics & Traumatology in Orthopedics & Traumatology
- Vol. 46 (2) , 316-318
I-cell Disease(Mucolipidosis II) A Case Report.
- 1 January 1997
- Published by West-Japanese Society of Orthopedics & Traumatology in Orthopedics & Traumatology
- Vol. 46 (2) , 316-318
Open AccessI-cell Disease(Mucolipidosis II) A Case Report.